ストックスクリーナーアプリを入手
1.67
6.37%
0.10
前日終値:
$1.57
開ける：
$1.58
24時間の取引高:
96,150
Relative Volume:
1.58
時価総額：
$4.65M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+13.61%
1か月 パフォーマンス:
-9.24%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.58
$1.7399
1週間の範囲:
$1.42
$1.7399
52週間の値動き範囲:
$1.41
$2.20
Vivosim Labs Inc Stock (VIVS) Company Profile
VIVS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.6892 | 4.65M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.22 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
535.38 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.87 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
546.01 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.23 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-12-13 | 開始されました | H.C. Wainwright | Buy |
| 2017-11-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 開始されました | Raymond James | Outperform |
| 2015-08-11 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 開始されました | Jefferies | Buy |
| 2015-06-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Vivosim Labs Inc (VIVS) 最新ニュース
VivoSim Labs, INC. SEC 10-K Report - TradingView
VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - The Globe and Mail
Analytical Overview: VivoSim Labs Inc (VIVS)’s Ratios Tell a Financial Story - DWinneX
VivoSim Labs (VIVS) Unveils NAMkind Platform with Leading Predictive Capabilities | VIVS Stock News - GuruFocus
VivoSim Labs, Inc. Showcases NAMkind™ Platform's Industry-Leading Liver Toxicology Prediction at Digestive Disease Week Conference - Nasdaq
VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - TradingView
VivoSim Labs regains Nasdaq compliance By Investing.com - Investing.com Nigeria
VivoSim Labs regains Nasdaq compliance - Investing.com
VivoSim Labs Avoids Nasdaq Delisting with Compliance Plan - TipRanks
Organovo Holdings, Inc. Announces Board Appointments - marketscreener.com
Organovo Announces Close Of Sale Of FXR Program To Eli Lilly And Company - marketscreener.com
Organovo: Fiscal Q2 Earnings Snapshot - marketscreener.com
Organovo Holdings, Inc. and BICO Reach Licensing Agreement on Bioprinting Patents - marketscreener.com
VivoSim Labs introduces AI-driven drug testing models By Investing.com - Investing.com Canada
VIVS: Riding the Market Waves of Growth and Decline in 2023 - investchronicle.com
Two new option listings and one option delisting on April 24th - TipRanks
VivoSim Announces Emergence from Stealth Mode To Provide Technol - GuruFocus
VivoSim Labs introduces AI-driven drug testing models - Investing.com Australia
VIVS Stock Price and Chart — NASDAQ:VIVS - TradingView
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market - The Manila Times
VivoSim Labs, Inc. Emerges from Stealth Mode to Revolutionize Drug Discovery with Non-Animal Toxicology Models Following FDA Initiative - Nasdaq
VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from - Bluefield Daily Telegraph
FDA Shift Powers VivoSim's Game-Changing Drug Testing Tech: 50% Cost Reduction Target - Stock Titan
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' - GuruFocus
Organovo (ONVO) Rebrands to VivoSim Labs with New Ticker 'VIVS' | ONVO Stock News - GuruFocus
Organovo announces VivoSim to carry forward 3D bioprinting, legacy tech - TipRanks
Organovo rebrands as VivoSim Labs, debuts new ticker - Investing.com
VivoSim to Carry Forward Organovo 3D Bioprinting | ONVO Stock Ne - GuruFocus
Organovo Holdings Announces Transition to VivoSim Labs - TipRanks
VivoSim to Carry Forward Organovo 3D Bioprinting - The Manila Times
Organovo Holdings Inc Name Change To VivoSim Labs Effective April 24, 2025 - TradingView
Strategic Transformation: Organovo Becomes VivoSim Labs to Accelerate 3D Bioprinting Innovation - Stock Titan
Organovo gets upfront payments following sale of its FXR Program to Lilly - Seeking Alpha
Organovo'S FXR Program, Including FXR314, To Be Acquired By Eli Lilly And Company - MarketScreener
Eli Lilly and Company entered into an asset purchase agreement to acquire FXR Program and Related Assets of Organovo Holdings, Inc. for $60 million. - MarketScreener
ONVO Stock Quote Price and Forecast - CNN
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings - marketscreener.com
ORGANOVO HOLDINGS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) - marketscreener.com
Organovo Holdings, Inc. Announces Executive Changes - marketscreener.com
ONVOOrganovo Holding Latest Stock News & Market Updates - Stock Titan
Keith Murphy Sends Letter to Shareholders of Organovo Holdings - marketscreener.com
Imagine Owning Organovo Holdings (NASDAQ:ONVO) And Trying To Stomach The 82% Share Price Drop - simplywall.st
Apparent Connections To A Convicted Stock Promoter: Another Chapter In The Organovo Saga (NASDAQ:VIVS) - Seeking Alpha
Vivosim Labs Inc (VIVS) 財務データ
Vivosim Labs Inc (VIVS) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.84%
0.47%
大文字化:
|
ボリューム (24 時間):